Postmenopausal Serum Sex Steroids and Risk of Hormone Receptor–Positive and -Negative Breast Cancer: a Nested Case–Control Study
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Prediagnostic endogenous sex steroid hormone levels have well established associations with overall risk of breast cancer. While evidence toward the existence of distinct subtypes of breast cancer accumulates, few studies have investigated the associations of sex steroid hormone levels with risk of hormone receptor [estrogen receptor (ER) and/or progesterone receptor (PR)] defined breast cancer. In a case–control study nested within the EPIC cohort (European Prospective Investigation into Cancer and Nutrition), estradiol, testosterone, and sex hormone–binding globulin levels were measured in prediagnostic serum samples from postmenopausal women not using hormone replacement therapy at blood donation. A total of 554 women who developed invasive breast cancer with information on receptor status were matched with 821 control subjects. Conditional logistic regression models estimated breast cancer risk with hormone concentrations according to hormone receptor status of the tumor. Sex steroid hormones were associated with risks of not only ER+PR+ breast cancer [estradiol OR for highest vs. lowest tertile = 2.91 (95% CI: 1.62–5.23), Ptrend = 0.002; testosterone OR = 2.27 (95% CI: 1.35–3.81), Ptrend = 0.002] but also of ER-PR- breast cancer [estradiol OR = 2.11 (95% CI: 1.00–4.46), Ptrend = 0.05; testosterone OR = 2.06 (95% CI: 0.95–4.46), Ptrend = 0.03], with associations appearing somewhat stronger in the receptor-positive disease. Serum androgens and estrogens are associated with risks of both hormone receptor–negative as well as receptor–positive breast tumors. Further research is needed to establish through which molecular pathways, and during which evolutionary stages of development, androgens and estrogens can promote the occurrence of both receptor-positive and -negative clinical breast tumors. Cancer Prev Res; 4(10); 1626–35. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing heterogeneity in meta-analysis: Q statistic or I² index?
Huedo-Medina, T. B., Sánchez-Meca, J., Marín-Martínez, F., & Botella, J. (2006) · Psychological Methods · doi:10.1037/1082-989x.11.2.193 · Cited by 4,256
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824 · cited 1×
“Serum concentrations of free testosterone and free estradiol (unbound to SHBG or albumin) were calculated from mass action equations using absolute concentrations of each steroid and SHBG, and assuming a constant serum albumin concentration of 43 g/L (23, 24).”
MethodRiboli, E., Hunt, K., Slimani, N., Ferrari, P., Norat, T., Fahey, M., Charrondière, U., Hémon, B., Casagrande, C., Vignat, J., et al. (2002) · Public Health Nutrition · doi:10.1079/phn2002394 · Cited by 1,866
Self-citationLabrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S.-X., & Pelletier, G. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0031 · Cited by 544 · cited 1×
“The specific role that androgens may have in breast cancer etiology has long been debated (33, 38).”
BackgroundSex steroid-producing enzymes in human breast cancer
Suzuki, T., Miki, Y., Nakamura, Y., Moriya, T., Ito, K., Ohuchi, N., & Sasano, H. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00834 · Cited by 182
Cited by
Physical activity and risk of breast cancer: a meta-analysis of prospective studies
Wu, Y., Zhang, D., & Kang, S. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2396-7 · Cited by 424
Epidemiology of Breast Cancer in Women
Coughlin, S. S. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-20301-6_2 · Cited by 331
Risk determination and prevention of breast cancer
Howell, A., Anderson, A. S., Clarke, R. B., Duffy, S. W., Evans, D. G., Garcia-Closas, M., Gescher, A. J., Key, T. J., Saxton, J. M., & Harvie, M. N. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0446-2 · Cited by 327
Self-citationStanczyk, F. Z., Mathews, B. W., & Sherman, M. E. (2015) · Steroids · doi:10.1016/j.steroids.2014.12.011 · Cited by 43
Menopausal hormone therapy and breast cancer
Santen, R. J. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.06.010 · Cited by 41
Metadata
- Authors
- James, R. E., Lukanova, A., Dossus, L., Becker, S., Rinaldi, S., Tjønneland, A., Olsen, A., Overvad, K., Mesrine, S., Engel, P., Clavel-Chapelon, F., Chang-Claude, J., Vrieling, A., Boeing, H., Schütze, M., Trichopoulou, A., Lagiou, P., Trichopoulos, D., Palli, D., Krogh, V., Panico, S., Tumino, R., Sacerdote, C., Rodríguez, L., Buckland, G., Sánchez, M.-J., Amiano, P., Ardanaz, E., Bueno-de-Mesquita, B., Ros, M. M., van Gils, C. H., Peeters, P. H., Khaw, K.-T., Wareham, N., Key, T. J., Allen, N. E., Romieu, I., Siddiq, A., Cox, D., Riboli, E., & Kaaks, R.
- Venue
- Cancer Prevention Research
- Published
- 2011-10-01
- Volume
- 4
- Issue
- 10
- Pages
- 1626-1635
- ISSN
- 1940-6207 (ISSN-L)
- 1940-6215
- OpenAlex
- W2114836367
- Cited by
- 122
- References
- 5
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Postmenopausal Serum Sex Steroids and Risk of Hormone Receptor–Positive and -Negative Breast Cancer: a Nested Case–Control Study. https://app.cochat.ai/papers/10.1158/1940-6207.capr-11-0090
- The paper
- James, R. E., Lukanova, A., Dossus, L., Becker, S., Rinaldi, S., Tjønneland, A., Olsen, A., Overvad, K., Mesrine, S., Engel, P., Clavel-Chapelon, F., Chang-Claude, J., Vrieling, A., Boeing, H., Schütze, M., Trichopoulou, A., Lagiou, P., Trichopoulos, D., Palli, D., . . . Kaaks, R. (2011). Postmenopausal Serum Sex Steroids and Risk of Hormone Receptor–Positive and -Negative Breast Cancer: a Nested Case–Control Study. Cancer Prevention Research. https://doi.org/10.1158/1940-6207.capr-11-0090
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.